Christopher M Reilly

Dr. Christopher M Reilly


Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 December 2009 in Small
Verified
Journal Article
Closed access
PDF file
SHSuzanne M. Hirst
Suzanne M. Hirst
AKAjay S. Karakoti
Ajay S. Karakoti
RTRon D. Tyler
Ron D. Tyler
NSNammalwar Sriranganathan
Nammalwar Sriranganathan
SSSudipta Seal
Sudipta Seal
CRChristopher M Reilly
Christopher M Reilly

1 January 2016 in Clinical Immunology
Verified
Journal Article
Open access
NRNicole L. Regna
Nicole L. Regna
MVMiranda D. Vieson
Miranda D. Vieson
XLXin Luo
Xin Luo
CCCristen B. Chafin
Cristen B. Chafin
APAbdul Gafoor Puthiyaveetil
Abdul Gafoor Puthiyaveetil
CRChristopher M Reilly
Christopher M Reilly
We sought to determine if a selective HDAC6 inhibitor (ACY-738) decreases disease in NZB/W mice. From 22 to 38weeks-of-age, mice were injected intraperitoneally with 5 or 20mg/kg of ACY-738, or vehicle control. Body weight and proteinuria were measured every 2weeks, while sera anti-dsDNA, Ig isotypes, and cytokine levels were measured every 4weeks. Kidney disease was determined by evaluation of sera, urine, immune complex deposition, and renal pathology. Flow cytometric analysis assessed thymic, splenic, bone marrow, and peripheral lymphocyte differentiation patterns. Our results showed HDAC6 inhibition decreased SLE disease by inhibiting immune complex-mediated glomerulonephritis, sera anti-dsDNA levels, and inflammatory cytokine production and increasing splenic Treg cells. Inhibition of HDAC6 increased the percentage of cells in the early-stage developmental fractions of both pro- and pre-B cells. These results suggest that specific HDAC6 inhibition may be able to decrease SLE disease by altering aberrant T and B cell differentiation.

5 January 2022 in Metabolites
Verified
Journal Article
Open access
PDF file
ASAshton K Shiraz
Ashton K Shiraz
EPEric Panther
Eric Panther
CRChristopher M Reilly
Christopher M Reilly
B lymphocytes play an important role in the pathophysiology of many autoimmune disorders by producing autoantibodies, secreting cytokines, and presenting antigens. B cells undergo extreme physiological changes as they develop and differentiate. Aberrant function in tolerogenic checkpoints and the metabolic state of B cells might be the contributing factors to the dysfunctionality of autoimmune B cells. Understanding B-cell metabolism in autoimmunity is important as it can give rise to new treatments. Recent investigations have revealed that alterations in metabolism occur in the activation of B cells. Several reports have suggested that germinal center (GC) B cells of individuals with systemic lupus erythematosus (SLE) have altered metabolic function. GCs are unique microenvironments in which the delicate and complex process of B-cell affinity maturation occurs through somatic hypermutation (SHM) and class switching recombination (CSR) and where Bcl6 tightly regulates B-cell differentiation into memory B-cells or plasma cells. GC B cells rely heavily on glucose, fatty acids, and oxidative phosphorylation (OXPHOS) for their energy requirements. However, the complicated association between GC B cells and their metabolism is still not clearly understood. Here, we review several studies of B-cell metabolism, highlighting the significant transformations that occur in GC progression, and suggest possible approaches that may be investigated to more precisely target aberrant B-cell metabolism in SLE.